Get the Stockscreener App
4.065
0.12%
0.005
Pre-market:
4.14
0.075
+1.85%
Voyager Therapeutics Inc stock is traded at $4.065, with a volume of 281.40K.
It is up +0.12% in the last 24 hours and down -7.19% over the past month.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
See More
Previous Close:
$4.06
Open:
$4.1
24h Volume:
281.40K
Relative Volume:
0.78
Market Cap:
$224.42M
Revenue:
$163.78M
Net Income/Loss:
$25.88M
P/E Ratio:
6.2538
EPS:
0.65
Net Cash Flow:
$-28.66M
1W Performance:
-1.81%
1M Performance:
-7.19%
6M Performance:
-34.96%
1Y Performance:
-55.53%
1-Day Range:
$3.97
$4.32
1-Week Range:
$3.56
$4.32
52-Week Range:
$3.56
$10.66
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Name
Voyager Therapeutics Inc
Sector
Industry
Phone
857-259-5340
Address
75 HAYDEN AVENUE, LEXINGTON, MA
Compare VYGR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
4.065 | 224.42M | 163.78M | 25.88M | -28.66M | 0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-02-24 | Initiated | Citigroup | Buy |
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Oct-16-24 | Initiated | Leerink Partners | Outperform |
| Mar-26-24 | Initiated | Guggenheim | Buy |
| Mar-19-24 | Initiated | H.C. Wainwright | Buy |
| Mar-07-24 | Initiated | Citigroup | Buy |
| Jan-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-10-23 | Initiated | Truist | Buy |
| Mar-10-23 | Initiated | Oppenheimer | Outperform |
| Oct-07-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-03-21 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-03-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-24-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-23-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-10-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-19-20 | Initiated | The Benchmark Company | Buy |
| Feb-06-20 | Initiated | Oppenheimer | Outperform |
| Nov-15-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Sep-10-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-18 | Initiated | H.C. Wainwright | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-12-18 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-02-18 | Initiated | Morgan Stanley | Overweight |
| Nov-28-17 | Resumed | Piper Jaffray | Overweight |
| Oct-31-17 | Initiated | Robert W. Baird | Outperform |
| Oct-27-17 | Initiated | Canaccord Genuity | Buy |
| Oct-23-17 | Reiterated | Stifel | Buy |
| Oct-12-17 | Initiated | Raymond James | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-28-17 | Resumed | Stifel | Buy |
View All
Voyager Therapeutics Inc Stock (VYGR) Latest News
Cantor Fitzgerald Reaffirms “Overweight” Rating for Voyager Therapeutics (NASDAQ:VYGR) - Defense World
Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates - MSN
Voyager Therapeutics’ Earnings Call Highlights Promising Future - TipRanks
A Glimpse Into The Expert Outlook On Voyager Therapeutics Through 4 Analysts - Nasdaq
Voyager Therapeutics stock hits 52-week low at $3.67 - Investing.com
Voyager Therapeutics stock hits 52-week low at $3.67 By Investing.com - Investing.com Australia
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2024 Earnings Call Transcript - Insider Monkey
Voyager Therapeutics price target lowered to $10 from $12 at Wells Fargo - TipRanks
Voyager Therapeutics Inc earnings missed by $0.22, revenue fell short of estimates - Investing.com
Voyager Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Voyager Therapeutics: Strong Financials and Promising Pipeline Drive Buy Rating - TipRanks
Voyager Therapeutics: Q4 Earnings Snapshot - mySA
Earnings call transcript: Voyager Therapeutics Q4 2024 sees stock dip post-earnings - Investing.com
Voyager Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
VOYAGER THERAPEUTICS Earnings Results: $VYGR Reports Quarterly Earnings - Nasdaq
Voyager Therapeutics, Inc. SEC 10-K Report - TradingView
Voyager Therapeutics Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - TradingView
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - GlobeNewswire
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - GlobeNewswire Inc.
VOYAGER THERAPEUTICS Earnings Preview: Recent $VYGR Insider Trading, Hedge Fund Activity, and More - Nasdaq
Rhumbline Advisers Increases Stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Voyager Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast - GlobeNewswire
John Stankey Updates Shareholders at Morgan Stanley Technology, Media & Telecom Conference on March 4 - The Globe and Mail
New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach - PharmaVoice
When Will Voyager Therapeutics Reveal Its Latest Neurogenetic Medicine Progress? - StockTitan
Voyager Therapeutics (NASDAQ:VYGR) Given “Buy” Rating at HC Wainwright - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc.VYGR - PR Newswire
Voyager Therapeutics Reports Positive Trial Results From Alzheimer's Disease Treatment - Marketscreener.com
Voyager Therapeutics Reports Positive Data From Single Ascending Dose Study Of VY7523 - Nasdaq
Voyager Therapeutics Reports Positive Topline Data for VY7523 in Alzheimer’s Disease Trials - Nasdaq
Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer's Disease - The Manila Times
Voyager Reports Positive Topline Data for Single Ascending - GlobeNewswire
Can Voyager's Anti-Tau Antibody Break Through in Alzheimer's Treatment? Phase 1 Results Show Promise - StockTitan
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Consensus Rating of “Buy” by Brokerages - Defense World
Voyager Therapeutics stock hits 52-week low at $4 - Investing.com India
Voyager Therapeutics stock hits 52-week low at $4 By Investing.com - Investing.com South Africa
Did Voyager Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky InvestigateVYGR - ACCESS Newswire
Allspring Global Investments Holdings LLC Raises Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
VYGR ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Voyager Therapeutics, Inc. Shareholders Who Lost Money - ACCESS Newswire
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences - The Manila Times
Positive Sentiment Still Eludes Voyager Therapeutics, Inc. (NASDAQ:VYGR) Following 27% Share Price Slump - Simply Wall St
Voyager Therapeutics COO Robin Swartz sells $16,549 in stock By Investing.com - Investing.com Australia
An Investigation Has Commenced on Behalf of Voyager Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your VYGR Losses. - ACCESS Newswire
VOYAGER ALERT: Bragar Eagel & Squire, P.C. is Investigating Voyager Therapeutics, Inc. on ... - The Hastings Tribune
Voyager Therapeutics Executives Cash In: Major Stock Sales Revealed! - TipRanks
VOYAGER ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Voyager Therapeutics CEO Alfred Sandrock sells $49,616 in stock By Investing.com - Investing.com Canada
Voyager Therapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
Voyager Therapeutics COO Robin Swartz sells $16,549 in stock - Investing.com India
Voyager Therapeutics CEO Alfred Sandrock sells $49,616 in stock - Investing.com India
Voyager Therapeutics Inc Stock (VYGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Voyager Therapeutics Inc Stock (VYGR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sandrock Alfred | President and CEO |
Feb 20 '25 |
Sale |
4.24 |
11,702 |
49,616 |
296,816 |
| Swartz Robin | COO & CBO |
Feb 20 '25 |
Sale |
4.25 |
3,894 |
16,550 |
98,397 |
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):